Related news from
Sun, 17 May 2026 21:13:37 +0000	Cencora Legal Probes Test Investor Confidence After Weaker Q2 Revenue Outlook Multiple law firms have launched investigations into Cencora (NYSE:COR) for potential securities law violations following its Q2 2026 results. The company reported revenue that missed prior estimates and reduced its revenue growth forecast, prompting the legal scrutiny. The investigations focus on whether Cencora and its management misled investors around the period of the reported results and updated outlook. Cencora, trading at $257.71 at the last close, is now under a spotlight that goes...
Sat, 16 May 2026 21:56:55 +0000	The Top 5 Analyst Questions From Cencora’s Q1 Earnings Call Cencora’s first quarter results came in below Wall Street’s revenue expectations, and the market responded negatively. Management pointed to several factors behind the underperformance, including faster-than-expected brand-to-biosimilar conversions at a large mail order pharmacy customer, impacts from recent manufacturer price reductions, and lingering effects from the loss of certain customers. CEO Robert Mauch emphasized the resilience of Cencora’s business model, noting ongoing growth in spec
Fri, 15 May 2026 13:25:03 +0000	Wells Fargo Maintains Overweight Rating on Cencora (COR) Cencora, Inc. (NYSE:COR) is one of the 10 Best Depressed Stocks to Buy in 2026. On May 11, 2026, Wells Fargo analyst Stephen Baxter lowered the firm’s price target on Cencora, Inc. (NYSE:COR) to $331 from $429 while maintaining an Overweight rating on the shares. The firm said the magnitude of the slowdown in U.S. […]
Thu, 14 May 2026 17:06:00 +0000	CAH Stock Down Nearly 9.4% YTD: Should You Buy, Hold or Sell? CAH shares are down 9.4% YTD, but strong specialty drug growth, rising earnings estimates and a raised outlook may signal upside.
Wed, 13 May 2026 14:40:00 +0000	Can CAH Sustain Growth on Booming Pharmaceutical & Specialty Segment? Cardinal Health's Pharmaceutical & Specialty segment posts strong Q3 growth, but can specialty momentum continue powering earnings?
Sat, 09 May 2026 21:04:45 +0000	Cencora Q2 Earnings Call Highlights Cencora (NYSE:COR) reported higher fiscal second-quarter adjusted earnings and operating income, while management raised its full-year adjusted EPS outlook and said it would resume opportunistic share repurchases. The pharmaceutical distribution and healthcare services company also lowered its full-
Thu, 07 May 2026 16:14:21 +0000	Is Cencora (COR) Prioritizing Margin Expansion Over Growth With Its Raised EPS Outlook and Buybacks? Cencora, Inc. has now reported its fiscal 2026 second-quarter results, with sales of US$78,355.92 million and net income of US$1,641.33 million, alongside a quarterly dividend of US$0.60 per share payable on June 1, 2026. Despite missing consensus revenue and EPS estimates and trimming full-year sales growth guidance, Cencora raised its adjusted EPS outlook and outlined plans for US$1 billion of share repurchases, highlighting a focus on profitability and capital returns even as top-line...
Thu, 07 May 2026 10:08:34 +0000	US Stock Market Today S&P 500 Futures Inch Higher As Inflation Worries Ease The Morning Bull - US Market Morning Update Thursday, May, 7 2026 US stock futures are slightly higher this morning, with E-mini S&P 500 contracts up about 0.1%, as investors balance cooler bond markets, cheaper oil, and fresh US jobs data. The US 10 year Treasury yield is holding near 4.35%, which means borrowing costs for mortgages and companies remain relatively elevated but are not climbing further for now. Hopes of a US Iran peace deal are pulling oil prices lower and easing some...
Wed, 06 May 2026 17:04:56 +0000	Cencora (COR) Q2 2026 Earnings Transcript Robert Mauch: Thank you, Bennett. Hi, everyone, and thank you for joining Cencora's Fiscal 2026 Second Quarter Earnings Call. In our fiscal second quarter, we saw operating income growth in both our U.S. and International Healthcare Solutions segments and delivered adjusted diluted EPS growth of 7.5%.
Wed, 06 May 2026 16:48:33 +0000	Cencora, Inc. Q2 2026 Earnings Call Summary Moby summary of Cencora, Inc.'s Q2 2026 earnings call
Wed, 06 May 2026 15:57:00 +0000	COR Stock Falls on Q2 Earnings & Revenue Miss, FY26 EPS View Raised Cencora shares sink after Q2 earnings and revenues miss estimates, even as the company raises its fiscal 2026 EPS outlook.
Wed, 06 May 2026 11:45:03 +0000	Cencora (COR) Misses Q2 Earnings and Revenue Estimates Cencora (COR) delivered earnings and revenue surprises of -1.04% and -2.98%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Wed, 06 May 2026 10:46:25 +0000	Cencora (NYSE:COR) Reports Sales Below Analyst Estimates In Q1 CY2026 Earnings Healthcare distributor Cencora (NYSE:COR) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 3.8% year on year to $78.36 billion. Its non-GAAP profit of $4.75 per share was in line with analysts’ consensus estimates.
Wed, 06 May 2026 10:30:00 +0000	Cencora Reports Fiscal 2026 Second Quarter Results CONSHOHOCKEN, Pa., May 06, 2026--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2026 second quarter ended March 31, 2026, revenue increased 3.8 percent year-over-year to $78.4 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $8.40 for the second quarter of fiscal 2026 compared to $3.68 in the prior year second quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, inc
Tue, 05 May 2026 22:05:18 +0000	Solventum (SOLV) Tops Q1 Earnings and Revenue Estimates Solventum (SOLV) delivered earnings and revenue surprises of +9.36% and +1.01%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Tue, 05 May 2026 14:32:00 +0000	Cencora to Report Q2 Earnings: What's in Store for the Stock? COR heads into Q2 earnings with expected steady specialty-driven growth, but customer losses and pricing pressures could temper results.
Mon, 04 May 2026 15:40:04 +0000	CON vs. COR: Which Stock Is the Better Value Option? CON vs. COR: Which Stock Is the Better Value Option?
Fri, 01 May 2026 13:15:08 +0000	Seeking Clues to Cencora (COR) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics Beyond analysts' top-and-bottom-line estimates for Cencora (COR), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2026.
Thu, 30 Apr 2026 14:00:21 +0000	Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Thu, 30 Apr 2026 04:30:00 +0000	2 Things Matter Most in Picking Winning Stocks, Says This Market Pro Adam Parker’s Trivariate Research analyzes stocks from a macro, fundamental, and quantitative perspective.

If you are already a Value Forum member but are not logged on, click here to log on. If you are a guest, thank you for visiting ValueForum -- click here for information about guest access or click here to join -- a Trial Pass can be purchased for $6.99 to help you decide if you want to commit to longer term membership. Did you know there are customized portals into VF like REITs.ValueForum.com and also My ValueForum which lets you customize your VF experience to the posters and topics that most interest you!